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Scientific edencesuggests thathumans andwildlifespecesmayexperience adversehealth conse-
quences from exposure to environmental chemicals that interact with the endocrine system.
Reliable short-term assays are needed to identifrhormone-dismpting chemicals. In this studywe
demonstrate that the estrogenic activity ofa chemical can be evaluated byassaying induction or
repression ofendogenous estrogen-regulated 'marker genes" in human breast cancer MCF-7
cells. Weinduded fourmarkergenes inthe assay -pS2, transforminggrowth factorP3 (TGa933),
monoamine oxidase A, and ecl-antichymotrypsin- and we evaluated estrogeniic acivity for 17P-
estradiol (E2), diethylstilbestrol, ci-zearalanol, nonylphenol, genistein, methoxychlor, endosul-
phan, o,p-DDE, bisphenol A, dibutylphthalate, 4-hydoxytamoxifn, and ICI 182.780. All four
marker genes responded strongly to the three high-potency estrogens (E29diethylstilbestol, and
-earalanol), whereas thepotencyofthe other chemicals was 103- to 106-fold lowerthan that of
E2. There were some maker gene-dependent differences in the relative potencies of the tested
chemicals. TG$P3wasequallysensitive to thethreehigh-potencyestrogens,whereasthesensitiv-
ity to oc-zearalanol was approximately 10-fold lower than the sensitivity toE2 and diethyistilbe-
strolwhen assayed with the other three marker genes. TIhe potencyofnonylphenol was equal to
that ofgenistein when assayed with pS2 and TG1f3, but 10- to 100-fold higherilower with
monoamine oxidase A and al-antichymotypsin, respectively. The results are in agreement with
results obtainedbyothermethodsandsuggestthat an assaybasedonendogenous gene expression
may offer an attractive alternative to other E-SCREEN methods. Key wordr. cri-antichy-
motrypsin, competitive PCR, differential display, endocrine disruptors, estrogen, estrogenicity
assay, gene expression, monoamine oxidase A, pS2, TGFiI3. Environ Health Perspect
108:403-412 (2000). [Online 17Marh 2000]
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The presence ofendocrine disruptors in our
environment has caused an increasing con-
cern oftheir possible impact on wildlife and
human health (1,2). Investigators have
focused on a possible decrease in human
semen quality and an undisputed increased
incidence of testicular cancer over the past
few decades (3,4). Although hypothetical,
these changes may be caused by intrauterine
exposure of the male fetus to estrogens or
antiandrogens (5). In addition, significant
increases in the incidences of prostate,
endometrium, and breast cancer, and mal-
formations of the external and internal
genitals have been observed over the past
40-50 years, and mayalso be associatedwith
increased exposure to estrogens (6a-8.
Environmental estrogens indude a variety
ofverydifferent chemicals such as polychlori-
nated biphenyls (PCBs), organochlorine pes-
ticides, alkylphenols, phthalates, and food
antioxidants (2,9-11). In addition, many
plants and fungi contain compounds with
estrogenic activity-the phytoestrogens and
mycoestrogens (2). The chemical structures of
these chemicals vary substantially, which
makes it difficult to predict their estrogenicity
solelyon astructural basis.
Hence, there is a strong need for reliable
short-term methods that can rapidly detect
chemicals with estrogenic properties. This is
reflected in the ambitious Endocrine Dis-
ruptor Screening and Testing Program
(EDSTP), which was recently proposed by
the U.S. Environmental Protection Agency
(EPA), for which the EPA is concidering
more than 87,000 substances as potential can-
didates for testing. These compounds include
pesticides, commercial chemicals, ingredients
in cosmetics, food additives, nutritional sup-
plements, and certain mixtures. The EDSTP
isavailable online from the EPAwebsite (12.
According to the EDSTP, the compounds
will be tested for effects on the estrogen,
androgen, and thyroid systems in humans,
fish, and wildlife by a combination of in vitro
and in vivo screening assays. The assays pro-
posed by the EPA to detect estrogenic chemi-
cals indude estrogen receptor (ER) binding
assays (13,14), transcriptional activation assays
(15), rodent 3-day uterotrophic assays (16),
rodent20-daypubertal female assays (1;), and
the fish gonadal recrudence assay (18). For
chemicals that are positive in the screening,
this will be followed bylonger-term studies to
determinewhether thechemicals cause adverse
effects in humans, fish, and wildlife and to
establish a quantitative relationship between
thedoseandtheadverse effect.
Short-term estrogenicity assays in the
EDSTP. Thevalidity and usefulness ofsome
of the assays included in the EDSTP and
other short-term estrogenicity assays was
recently evaluated in a comparison study by
Andersen et al. (1).
The in vitro assays are based either on
measurement of direct binding to isolated
receptors or on the induction of a reporter
gene regulated through the ER. ER binding
assays involve the competition of the test
compoundwith radiolabeled estradiol forspe-
cific binding to the ER in whole cells or in
cell homogenates (13,14). Alternatively, spe-
cific binding to isolated recombinant recep-
tors could be measured (19,20). The direct
binding assay can easily be automated and
thus scaled to accommodate testing ofa large
number of compounds. However, the ER
binding assay only shows howwell the tested
compound binds to the ER, but it does not
define the ligand as an agonist or antagonist.
Furthermore, chemicals that are metabolized
to estrogenic compounds in mammalian cells
are notdetected in thecell freebindingassays.
In reporter gene-based assays, yeast or
mammalian cells are transfected with the
human ER and a reporter gene, such as -
galactosidase orluciferase, under thecontrol of
an estrogen responsive promoter. The activity
of the reporter gene is directly related to the
transcriptional activation activity of the test
compound (15). The yeast-based reporter
gene assays can easily be automated, but they
do not discriminate between estrogenic and
antiestrogenic chemicals (19,20). Mammalian
reporter gene assays are under development,
and they may eventually replace the current
yeast-based assays (21-23).
In the rodent 3-day uterotrophic assay,
estrogenicity is estimated as an increase in
uterine tissue mass in ovariectomized or
immature rodents after 3 days of treatment
(16); in the rodent 20-day pubertal female
assay, estrogenicity is indicated by accelerated
vaginal opening in weanling rats after daily
treatment beginning at 21 days of age (17).
Another commonly used in vivoestrogenicity
assay measures the level of the yolk protein
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vitellogenin in male fish, which is very low in
male fish but increases in a dose-dependent
manner after exposure to estrogenic com-
pounds (18); this is one of the primary end
points in the fish gonadal recrudescence
assay. The in vivo assays have several advan-
tages, especially the following: they take into
concideration the effects ofmetabolism, plas-
ma-protein binding, and pharmacokinetics;
and they typically cover a broader range of
mechanisms of actions than in vitro assays.
Because oftheir cost, complexity, and ethical
concerns, however, animal models are not
suited forlarge-scale screeningofchemicals.
Currently used alternative assays. There
are several attractive short-term assays that
are not included in the EDSTP, including
the cell proliferation assay (E-SCREEN)
described by Soto et al. (9). The E-SCREEN
assay is based on the dose-response relation-
ship between the proliferation of human
estrogen-dependent breast cancer cells and
the concentration of estrogen to which the
cells are exposed during 6 days ofincubation
(9). The sensitivity ofthe E-SCREEN assay
is relatively high, and it can discriminate
between estrogen agonists and antagonists.
However, the proliferative response is an
indirect effect, and the assay is complicated
by the toxicity ofsome compounds. Also, it
is undear to what degree proestrogens may,
or may not, be activated to their estrogenic
form in cultured cells.
In a clinical setting, the radioimmunoas-
say (RIA) is commonly used to measure
serum estradiol concentrations. Because it is
antibody-based, the RIA can only measure
17,B-estradiol (E2), although similar assays
probably could be developed for other com-
pounds. However, RIA assays have a detec-
tion limit of 10-20 pmol/L and cannot be
used to measure, for example, the concentra-
tion ofestadiol in the serum ofprepubertal
children (24).
Recently, Nishikawa et al. (25) proposed
an assay based on yeast two-hybrid measure-
ments of protein-protein interactions
between ER and coactivators. Because estro-
gen agonist binding leads to the dissociation
of corepressors and recruitment ofcoactiva-
tors, this assay measures both the ability ofa
compound to bind to the receptor and
whether it recruits coactivators; therefore, it
yields more information than a simple bind-
ing assay. Furthermore, other protein-protein
interactions could be included: for example,
interactions with corepressors could discrim-
inate between agonists and antagonists
because antagonists generally do not displace
corepressors.
The sensitivity of the currently available
assays, measured as the lowest detectable con-
centration ofestradiol, is very different. The
most sensitive is the MCF-7 cell proliferation
assay, in which concentrations as low as 0.1
pM can be measured (9); this assaymayactu-
ally be able to measure concentrations in the
femtomolar range (26). The yeast-based
reporter gene assays are generally several
orders of magnitude less sensitive (27),
although measurements ofvery low estradiol
concentrations have been reported (15). The
fish vitellogenin assay can detect estradiol at
approximately 4 pM (18), whereas direct
binding assays generally require concentra-
tions in the nanomolar range (19,28).
Thus, there is a need for additional very
sensitive assays that can be used to verify
results obtained by, for example, MCF-7 cell
proliferation assays.
Assaying the expression levels ofendoge-
nous genes. An alternative assay could be
based on quantitation of estrogen-induced
changes in the expression levels of endoge-
nous genes, either in cultured cells or in
selected tissues from exposed animals. For
example, Petit et al. (29) measured the induc-
tion ofvitellogenin in trout hepatocyte cul-
tures to identifyestrogeniccompounds. With
an endogenous gene expression assay, it is
possible to assay for induction ofgenes that
are known to be regulated bydifferent signal-
ing pathways as well as for genes that are
regulated directly by the ER. Compared to
this, a reporter gene assay will only reveal
how a single gene or promoter is regulated;
for example, effects caused by cross-talk
between different signaling pathways may
not be detected. In addition, assaying gene
expres-sion in several tissues from exposed
animals ensures that effects derived both
from the test compound and from its
metabolites are detected, including tissue-
specific effects.
In the end, all the end points currently
used to determine estrogenicity in animals
(and cells) are derived from changes in gene
expression, and these changes in the expres-
sion of endogenous genes could be as good
an end point as, for example, increased uter-
ine weight, provided the responsible genes
have been identified.
In this study we show that a cell-based
endogenous gene expression assay isverysen-
sitive and that it can be used to assay the
estrogenicity ofdifferent putative estrogenic
chemicals (Figure 1). Estrogenicity is evaluat-
ed as induction or repression offour endoge-
nous estrogen-regulated "marker genes"
selected from a collection ofpreviously iden-
tified estrogen-regulated genes. The assay is
performed in human estrogen-dependent
breast cancer MCF-7 cells, and changes in
gene expression are assayed by a competitive
polymerase chain reaction (PCR) method
and displayed on PAGE gels as for differen-
tial display of reverse transcribed mRNAs
technology (DDRT-PCR) (30,31). The
expression levels are subsequently quantitated
byphosphor imaging.
Materials and Methods
Detailed step-by-step manuals for all proce-
dures related to DDRT-PCRcan be obtained
from the DD Baseweb site (32.
Cellculturingandhormone exposure. To
avoid any sample-to-sample contamination,
we cultured all cells used in this study in 25
cm2 flasks. Human estradiol-dependent
MCF-7 breast cancer cells (a gift from P.
Briand; The Danish Cancer Society, Copen-
hagen, Denmark) were grown in DMEM
medium (Gibco BRL, Rockville, MD)
containing 5% fetal bovine serum (FBS;
Gibco BRL), 1 nM insulin (Roche, Basel,
Switzerland), 2 mM L-glutamine (Gibco
BRL), 1 x nonessential amino acids (Gibco
BRL), and 25 IU/mL penicillin-streptomycin
(Gibco BRL). The medium was changed
every 2-3 days. Six days before the addition
Figure 1. Chemical structures ofthe compounds used in the study.
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ofthe test compounds, the cells were washed
in phosphate-buffered saline (PBS; Gibco
BRL), andthe mediumwassubstitutedwith a
phenol red-free DMEM medium (Gibco
BRL) containing 5% dextran charcoal-
stripped FBS and the standard additives
described above. Steroids were removed from
FBS essentially as described by Darbre et al.
(33). Briefly, FBS was incubated with 0.5%
activated charcoal (Sigma-Aldrich, St. Louis,
MO) and 0.05% dextran T-70 (Amersham
Pharmacia Biotech, Uppsala, Sweden) for 30
min at 55°C; the charcoal particles were
removed by centrifugation at 4°C for 20 min
at 4,500g. This step was repeated, and the
stripped serum was sterile filtered and stored
in aliquots at -20°C. Forty to 50% confluent
cells were rinsed in PBS, and fresh medium
containing the respective test compound was
added. The control cells received only the
vehicle (ethanol).
Testchemicals. The test compounds were
bisphenol A (BisA; I-0635; Sigma-Aldrich);
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene
(o,p-DDE; 12,389-7; Sigma-Aldrich);
dibutylphthalate (DBP; D-2270; Sigma-
Aldrich); diethylstilbestrol (DES; D-4628;
Sigma-Aldrich); endosulphan (ES; C131200;
Ehrenstorfer Gmbh, Augsburg, Germany); E2
(E-2758; Sigma-Aldrich); genistein (GS;
G-6649; Sigma-Aldrich); methoxychlor (MC;
M-1501; Sigma-Aldrich); nonylphenol tech-
nical grade (NP; 29,085-8; Sigma-Aldrich];
4-hydroxy tamoxifen (4-OH-TAM; H-6278;
Sigma-Aldrich); ICI 182.780 (AstraZeneca
Pharmaceuticals, Westborough, MA); and a-
zearalanol (ZA; Z-0292; Sigma-Aldrich).
Isolation ofRNA. Cellswere harvested by
adding 1 x trypsin-EDTA (Gibco BRL) and
collected by centrifugation (1,000g for 5
min.). Total RNA was prepared using the
RNeasy total RNA kit (Qiagen, Hilden,
Germany) as described by the manufacturer,
and stored in diethylpyrocarbonate-treated
H20 (DEPC-H20) at -80°C. Contaminat-
ing DNA was removed from the total RNA
by treating with 5 U DNase-1 (Amersham
Pharmacia Biotech) in 20 mM Tris-HCI, pH
7.5, and 7.5 mM MgCl2 at 37°C for 30 min.
The DNase was removed by incubation with
25 ig/mL proteinase K in 5 mM Tris-HCI,
pH 7.5, and 10 mM EDTA, pH 8.0, at
37°C for 15 min. The RNA was then
extracted with phenol/chloroform and col-
lected by ethanol precipitation. The total
RNA was dissolved in DEPC-H20 at a con-
centration of1-5 pg/pL and stored at-80°C.
cDNA synthesis. One microgram total
RNAand0.5 pgHT1lVprimer (Table 1) in
10 pL DEPC-H20 were mixed and heated
to 650C for 1 min. The samples were quickly
transferred to 420C, and 10 1L cDNA
Synthesis Mix and 7-8 U AMV Reverse
Transcriptase (Stratagene, LaJolla, CA) were
added. The final composition ofthe reaction
buffer was 130 mM Tris-HCl, pH 8.3; 5
mM MgCI2, 20 mM KCI, and 0.625 mM
each of deoxyribonucleoside triphosphates
(dATP, dCTP, dGTP, and dTTP). The
samples were incubated at 420C for 1 hr,
and then 80 pL of 0.1% Triton X-100 in
H20 was added. The samples were dena-
tured at 950C for 1 min and stored in
aliquots at 800C.
CompetitivePCR One microliter cDNA
was used in competitive PCR reaction mix-
tures performed in total volumes of 12 1lL
(final concentrations, including contribu-
tions from the cDNA): 12 mM Tris-HCI,
pH 8.3; 50 mM KCI; 1.9 mM MgCI2; 0.1%
Triton X-100; 0.005% gelatin; 14 pM each
dATP, dCTP, dGTP, and dTTP; 1 pCi
[35S]adATP (Amersham Pharmacia Biotech);
10 pmol each upstream and downstream
primers (Table 1, Table 2); and 1 U
AmpliTaq (Perkin-Elmer, Norwalk, CT).
PCRwas performed in a Perkin-Elmer 9600
PCR machine (Perkin-Elmer) and the cycle
conditions were as follows: 1 cycle of2 min
at 950C and 40 cycles of 30 sec at 950C, 1
min at 400C, 1 min at 720C, and 1 cycle of
5 min at 72°C. After PCR, 10 pL loading
buffer (8% ficoll 400, 10 mM EDTA, 10
mM NaOH, 0.1225% bromophenol blue,
and 0.1225% xylene cyanol in formamide)
was added and the samples were denatured
for 2 min at 96°C. Samples were then
loaded onto a 5% polyacrylamide "sequenc-
ing type" gel run on the ALF-Express seque-
nator (Amersham Pharmacia Biotech). After
electrophoresis at 25 W for 3 hr, gels were
transferred to Whatmann 3 MM paper
(Whatmann, Maidstone, UK), dried, and
analyzed by autoradiography and phosphor
imaging.
Amplification ofcDNAfragmentsfrom
differential displaygels. We excised differen-
tially expressed bands from the dried gels and
recovered the DNA content by shaking the
sample in 50 pLTe buffer (10 mM Tris-HCI,
pH 7.5; 0.1 mM EDTA) at95°Cfor 15 min.
We used 5 pL for PCR amplification in a
total volume of27 pL (final concentrations)
10 mM Tris-HCl, pH 8.3; 50 mM KCI; 1.8
mM MgCl2; 0.1% Triton X-100; 0.005%
gelatin; 70 pM each dATP, dCTP, dGTP,
and dTTP; 2.5 U AmpliTaq (Perkin-Elmer);
10 pmol upstream primer; and 10 pmol
"extended" downstream primer (T7HT1 1V;
Table 1). Cycle conditions were as described
Table 1. Downstream primers.
Primer Sequence
cDNA synthesis and differential display(HT11V and HT11VN)
HT11A
HTllC
HTllG
HT11AC
HT1 1AG
HT1 1GA
HTllGG
HT11CC
HT11CT
Amplification (T7HT11V)
T7HT11A
T7HT11C
T7HT11G
Sequencing(T7)
SEQ-T7
AAGCI1I111111TTA
AAGCIIIIIFIITTIC
AAGC111111IIIG
AAGCI1I111111IAC
AAGCITIIIITIIIIAG
AAGC1111111TIIGA
AAGCIIIIIIIIITTGG
AAGCIIIIIIIITIICC
AAGCI TI ICT
TAATACGACTCACTATAGGGAAGCIIIIIIIIITTA
TAATACGACTCACTATAGGGAAGCII1111 IIIIC
TAATACGACTCACTATAGGGAAGCT IIIIIIIIIIG
CY5-TAATACGACiCACTATAGGGAA
Table2. Selected estrogen-regulated genes in human breast cancer cells.
Downstream
Identity Accession no. Upstream primer primer Size (bp) Regulation
al-Antichymotrypsin J05176 CCCTCCMCTGCATTAGa HT11C 380 1
EBP50 AF015926 AGCACTGATTCCCAGTTA HT11GG 600 1
p-Liv U41060 GTGCTTCAGTGCTa HT1 1GA 150 1
pS2 X00474 TTCCTGGTGTCACa HT11G 350 1
EST AC005384 CAAAGGTACTCCMAT HT11GG 250 1
EST AA677552 AGCACTGATTCCCAGTTA HT11CT 180 1
EST AA291280 CACGCATAGACTG HT11AC 170 1
Monoamine oxidase A X60819 CTGTCTGTCCCAGTTAAa HT11GG 250
Ribosomal protein L9 U09953 ACTACCTCAGTTCTCAA HT11CC 300
TGF33 X14149 CACGCATAGACTGa HT11AG 140
EST AA731207 AGCACTGATTCCCAGTTA HT11CC 280 4-
EST AA772139 AGCACTGATTCCCAGTTA HTi 1CC 200 1
EST H81588 AGCACTGATTCCCAGTTA HT11GG 300 4-
Abbreviations: EBP50, ezrin-radixin-moesin binding phospho protein; EST, expressed sequence tag; TGF,3, transforming
growth factor13. Arrows indicate regulation by 17,B-estradiol: upregulated (1'),downregulated (41).
'indicates thatthe upstream primer is atargeted primer; downstream primer sequences are presented in Table 1.
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for differential display above, except that the
annealing temperature was 42°C. Reampli-
fled DDRT-PCR fragments were purified
from 2% agarose gels as follows: the frag-
ments were carefullyexcised from the agarose
gel and transferred to tubes containing small
siliconized glass wool plugs. A hole was
pinched in the bottom ofeach tube, and the
DNA/buffer spun out of the agarose piece
and into another tube.
We performed sequencing reactions as
cycle sequencing (34) using the Thermo-
Sequenase enzyme (Amersham Pharmacia
Biotech) and a "T7 promotor complemen-
tary" primer (Seq-T7; Table 1) that matched
all fragments amplified with the extended
T7HT11Vprimers (31). We usedALFexpress
sequenators (Amersham Pharmacia Biotech)
for all sequencing and DDRT-PCR gel
electrophoresis.
Quantitation of expression levels.
DDRT-PCR gels and Northern blots were
analyzed on a Fujifilm Bas-2500 phosphor
imager (Fuji, Tokyo, Japan). We adjusted
exposure time to the level ofradioactivity on
the gels/blots (between 3 and 24 hr). We
normalized lane-to-lane variation in intensi-
ty either by counting a constant band or by
correcting according to the background
immediately above or below the quantitated
band. The marker band in one lane was
framed, using the software supplied with the
phosphor imager, and the same frame was
then copied to the corresponding band in
the other lanes to ensure that identical areas
were used in all lanes. To normalize the
intensity of the different lanes, the marker
band frames were subsequently copied
together and moved to another position,
covering either a constant band or a blank
area (background) dose to the marker band.
All frames were then counted by the phos-
phor imager software, and thedatawas trans-
ferred to MS Excel (Microsoft, Redmond,
WA). We selected one lane and calculated
the ratios between a constant band or back-
ground in that lane and the values counted
at the corresponding position in each ofthe
other lanes. We used these ratios to normal-
ize the intensities of the marker bands by
multiplying the counts in each marker band,
after subtracting the backgroundvalue deter-
mined in that lane, with the corresponding
ratio.
We used the following formula for nor-
malization:
NMBiane 1 = (MBAane 1 BGlane1)
x (CBanei/CBane1) and
NMlane 2
= (MBiane 2
-BGlane2)
X (NCnal e1/ CMBane2); etc.,
where N= normalized, MB= marker band,
BG= background, and CB = constant band.
Results
We developed the endogenous gene-based
assay because in a screening for estrogen-reg-
ulated genes, we observed a strong correla-
tion between the expression of some genes
and the concentration of estrogen in the cell
media. This suggested that expression of
endogenous genes could be a useful method
for assaying the estrogenicity ofcompounds
and that individual genes could respond dif-
ferently to different estrogens. To evaluate
whether endogenous gene expression could
be used to assay compounds for potential
estrogen activity, we first optimized the dif-
ferent steps in the procedure and then tested
the estrogenicity ofa range ofcompounds.
Adjustment to "estrogen-free" cell culture
conditions. To determine the time needed for
the cells to adjust their gene expression to
"estrogen-free" conditions, we culturedMCF-
7 cells in a standard DMEM medium and
transferred them to an estrogen-free medium;
RNA was harvested on 6 consecutive days.
The expression level ofthe estrogen-inducible
pS2 mRNA, a widely used indicator ofestro-
genicity, was evaluated by DDRT-PCR using
a targeted upstream primer. This demonstrat-
ed that the level of pS2 mRNA expression
was relatively high when the cells were cul-
tured in the standard DMEM medium and
that the level decreased in a time-dependent
manner after incubation in the estrogen-free
medium (Figure 2). After 3-4 days, the
expression level ofpS2 was reduced sufficient-
ly to perform the experiments. However, to
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Figure 2. Adjustment of gene expression to estro-
gen-free cell culture conditions in MCF-7 cells cul-
tured in a standard DMEM medium, transferred to
an estrogen-free medium, and harvested on 6 con-
secutive days. (A) pS2 (indicated by arrow) was
detected using DDRT-PCR. (B) Quantitative esti-
mate of the relative change in gene expression
was obtained using phosphor imaging and pS2
and HT11G primers (Tables 1 and 2).
ensure that the cells adapted completely to
estrogen-freeconditions, all experiments were
performed on cells that were incubated for at
least 6 days in estrogen-free medium.
Screeningfor estrogen-regulatedgenes in
MCF-7 cells. The use ofendogenous genes
and the DDRT-PCR technology to assay for
estrogenicity implies the prior identification
ofestrogen-regulated bands, corresponding to
potential marker genes, on DDRT-PCRgels.
Thus, we screened MCF-7 cells that were
either unexposed or exposed to 10-8M E2 for
24 and 48 hr, respectively, for estrogen-regu-
lated genes, using random 13-mer upstream
primers and anchored poly-dT downstream
primers. Application ofmore than 400 differ-
ent primercombinations resulted in detection
ofalmost 100 estrogen-responsive genes (35).
Some ofthese are listed in Table 2 together
with their corresponding accession numbers,
upstream primer sequences, and the size and
regulation ofthebands.
Because most primer combinations result
in the display of 100-150 bands, the expres-
sion levels of40,000-60,000 bands have been
investigated. Comparing this with the
20,000-30,000 genes which are expressed in
ahuman cell at agiven time (36) suggests that
the majority of the estrogen-regulated genes
in MCF-7 cells mayhavebeen detected.
Optimization ofthe endogenous gene
expression assay. The most important para-
meter in selecting a marker gene is that its
expression is highly sensitive to the treat-
ment, that is, the intensity of the corre-
sponding band must be very different in
estrogen-treated cells and untreated cells.
Moreover, the gene must be directly regulat-
ed by estrogens and not be dependent on
prior induction of another gene, and its
induction must be reversed by the pure
antiestrogen ICI 182.780.
To test the different candidate marker
genes, we exposed MCF-7 cells to either
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Figure 3. Application of targeted upstream
primers increased sensitivity in cells exposed to
ethanol (control) or increasing concentrations of
E2. The band corresponding to the pS2 mRNA
(indicated by arrow) was detected using DDRT-
PCR with either a nontargeted upstream primer
(p-Liv) and HT11G (A) or a targeted upstream
primer(pS2) and HT11G (B) (Tables 1 and 2).
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increasing concentrations of test compound
for 24 hr or a fixed concentration for differ-
ent time periods. The candidate genes were
then assayed for dose- and time-dependent
effects on mRNA expression as reflected in
the intensity of the corresponding bands.
The initial selection reduced the number of
candidate marker genes to approximately 20
that all responded strongly to estradiol.
In this paper we present estrogen-
dependent expression profiles for four
representative marker genes: pS2, mono-
amine oxidase A (MAO-A), transforming
growth factor [3 (TGFP3) and al-antichy-
motrypsin (al-ACT).
Optimization ofPCR. For the 20 origi-
nallyselected genes, we improved the PCRby
optimizing the matches between primers and
mRNAbecause therewere several mismatches
in the alignment of the random upstream
primer sequences used in the screening and
the mRNA sequences. We designed the tar-
geted upstream primers bycorrecting the mis-
matches and extending the primer with four
to five extra nudeotides at the 5' end. Thus,
combining the targeted upstream primerwith
the appropriate downstream primer results in
a band of the same size as in the screening
(31). Because the primer position is impor-
tant for the efficiency of PCR amplification,
several targeted primers were tested for each
gene, and the primer that resulted in the
strongest bandwas selectedforfurther testing.
In most cases, the use oftargeted primers
significantly increased the sensitivity of the
assay. For example, with a random upstream
primer that contained three mismatches
within the 3'-six nucleotides ofthe primer, a
concentration of 10-10 M E2 was required to
induce a detectable increase in the expression
ofpS2 (Figure 3A), whereas application ofa
targeted upstream primer reduced the
required concentration to only 10-12 M
(Figure 3B).
To further enhance the assay, it can be an
advantage to reduce the number ofcompet-
ing bands, which can be done by replacing
the one-base-anchored downstream primer
(HT11V; Table 1) with a two-base-anchored
primer (HTIIVN; Table 1). In this study,
we used two-base-anchored downstream
primers for TGF13and MAO-A.
Rapid induction ofmarkergenes by EZ
The observed changes in gene expression
could, in principle, be caused by the activa-
tion or repression of other genes, for
example, a transcription factor that is directly
regulated byestrogen. The expression profiles
of genes directly regulated by estrogens sug-
gest that primary effects of estrogen are
induced within a few hours, whereas sec-
ondary effects are not detectable before
16-72 hr incubation (20). We therefore per-
formed a time-course study in which MCF-7
cells were exposed to E2 for increasing peri-
ods oftime (0, 2, 8, 16, 24, and 48 hr). For
almost all estrogen-responsive genes detected
in the screening, including the four marker
genes presented in this paper, the changes in
gene expression were detectable within 2-8
hr, suggesting that they are primary effects of
E2(Figure 4).
Estrogen-inducedchanges in markergene
expression are ER mediated. To verify that
the regulation was mediated by the ERs, we
tested the ability ofthe pure antiestrogen ICI
182.780 to inhibit the E2-induced changes in
gene expression. For all four marker genes,
ICI 182.780 abolished the effect of E2 in a
dose-dependent manner (Figure 5), demon-
strating that the observed effects are mediated
by the ERs. In fact, ICI 182.780 further
reduced or induced the expression levels as
compared to ethanol-only samples, which
suggests that there are trace amounts of
estrogens in the stripped serum, whose
effects are reversed by ICI 182.780. The
antiestrogen-mediated repression ofal-ACT
is difficult to detect because the concentration
ofE2 used in the competition experiment was
relatively low (10-1 M) and a 10-fold higher
concentration is required to significantly
inducealc-ACTexpression.
The results presented in this paper are
most likely derived only from activation of
ERa becausewe have not been able to detect
the ER[B mRNA in MCF-7 cells by RT-
PCR, not even with nested primers and 2 x
40 PCRcycles.
Consistency ofthe technology. Although
MCF-7 cells respond strongly to estrogens,
the technology used to assay gene expression
should be sufficiently robust and results
should be reproducible. Because the expres-
sion levels are determined by competitive
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Figure 4. Time-dependent effects of 171-estradiol on marker gene expression.
MCF-7 cells were exposed to 10-8 M E2 for 2, 8, 16, 24, or 48 hr and control cells
were exposed to ethanol (EtOH) for 24 hr. Bands corresponding to the four
marker genes (pS2, al-ACT, TGFJ3, and MAO-A; indicated by arrows) were
detected by DDRT-PCR using the following primers: pS2/HT11G (pS2), aXl-
antichymotrypsin/HT11C (al-ACT), TGFP3/HT11AG (TGFf3), and monoamine
oxidase AIHT11GG (MAO-A) (Tables 1 and 2).
Figure 5. Dose-dependent inhibition of E2-mediated changes in gene expres-
sion by ICI 182.780. MCF-7 cells were exposed to a fixed concentration of E2
(10-8 M) and increasing concentrations of ICI 182.780 for 24 hr. Bands corre-
sponding to the marker genes (indicated by arrows) were detected by DDRT-
PCR using the following primers: pS2/HT11G (pS2), al-antichymotrypsin/HT11C
(a1-ACT),TGFPI3/HT11AG (TGFj3), and monoamine oxidase A/HT11GG (MAO-A)
(Tables 1 and 2).
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PCR amplification of cDNA synthesized
from different RNA samples, it is important
thattheprotocols do not introducesignificant
variation. In addition, because it is impossible
to obtain completely identical loading on
DDRT-PCR gels, it must be possible to nor-
malize the lanes, according to either the back-
groundorto aconstant band.
To test theconsistencyofthe method, we
performed three cDNA synthesis reactions
from a single RNA preparation, followed by
three PCR runs of each cDNA; the results
for the pS2 primer set are shown in Figure
6A. The DDRT-PCR gel was scanned by
phosphor imaging and the results normalized
according to the back-ground just below the
pS2 band (Figure 6B). This showed that the
variation introduced by the cDNA synthesis
and PCRwas < 24 and 16%, respectively, and
that the maximal variation between two sam-
ples was < 34%. These differences are repre-
sentative ofthe variation we have observed
among the hundreds of samples that have
been analyzed; this variation is small as com-
pared to the severalfold differences among
samples treated with different concentrations
ofestrogens.
To test the power ofthe normalization,
two-thirds and one-third ofthevolume ofthe
sample in lane 9 (sample C/3) were loaded
separately (Figure 6A, lanes 10, 11, and 12).
After normalization, the pS2 values in these
lanes were essentially identical, showing that
normalization according to thebackground or
a constant band can be used to normalize
samples, evenwhen the loaded amounts differ
by300% (Figure 6B, lanes 10, 11, and 12).
Identification ofestrogenic chemicals.
We used the four marker genes to estimate
the estrogenicity of the following com-
pounds: E2, ZA, DES, GS, NP, BisA, DBP,
MC, ES, DDE, 4-OH-TAM, and ICI
182.780. The relative potencies ofthe tested
compounds on the expression of the four
genes areshown in Table 3.
Induction ofpS2 mRNA expression.
Induction of pS2 mRNA is a widely used
indicator ofestrogenicity (9,11,37), and pS2
mRNA was detected several times in the
screening. It is rapidly and strongly induced
by estrogens; therefore, we selected pS2 as
one of the marker genes. Because its expres-
sion is so strongly correlated to the level of
estrogen, we routinely, as a first approach,
test acompound for abilityto induce thepS2
gene. Thus, for all test compounds, we
assayed the induction of pS2 mRNA by
DDRT-PCR (Figure 7) and quantitated the
expression profiles by phosphor imaging
(Figure 8).
The expression level ofpS2 mRNA was
increased in a dose-dependent manner by all
the tested estrogens; however, their potencies
were very different. Based on their relative
potency (Table 3), the chemicals can be
divided into three groups. Group 1 includes
E2, ZA, and DES, which cause detectable
increases in pS2 at 10-12 M-10-'1 M; Group
2 includes NP and GS, which induce pS2 at
103- to 104-fold higher concentrations
(> 10-8 M); and Group 3 includes BisA,
DDE, MC, ES, and DBP, which require
105- to 106-fold higher concentrations, rela-
tive to E2, to induce pS2 (Figure 7, Figure
8). The high-potency estrogens in Group 1
(E2, ZA, and DES) cause a significantly
greater quantitative change in the expression
level ofpS2 as compared to the environmen-
tal estrogens in Groups 2 and 3. For exam-
ple, the expression level of pS2 is increased
almost 25-fold after exposure to E2 (10-10
M), but less than 10-fold after exposure to
DBP (104 M) (Figure 7, Figure 8).
Aslight increase in the expression level of
pS2 mRNA was also observed after exposure
to high concentrations (> 10-7 M) of4-OH-
TAM (Figure 7, Figure 8).
Dose-dependent effects ofestrogens and
antiestrogens on three other marker genes.
To increase the strength ofthe estrogenicity
assay and to analyze whether other genes
responded in the same manner as pS2, we
assayed dose-dependent effects of the test
compounds on thethreeothermarkergenes.
Exposure to increasing concentrations of
E2 caused an induction of al-ACT and a
reduction in the expression levels ofTGF,3
andMAO-A (Figure 9). Detectable reductions
in the expression levels ofTGFO3 and MAO-
Acould be detected at an E2 concentration of
pS2
L' e , E
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Figure 6. Competitive PCR amplification is a highly
consistent technology; from a single RNA sample,
three independent cDNA synthesis reactions were
performed (A, B, and C), followed by three PCR
reactions of each cDNA (1, 2 ,and 3). (A) The band
corresponding to pS2 (indicated by arrow) was
detected by DDRT-PCR using the pS2 and HT11G
primers. An equal volume of the sample in lane 9
(C/3) was loaded in lane 10 (vol = 1), and 2/3 and
1/3 the volume were loaded in lanes 11 and 12,
respectively. (B) After quantitation by phosphor
imaging, the values were normalized according to
the background in each lane.
10-13 M (Figure 9), equivalent to, or even
below, the dose required to induce pS2
mRNA expression (Figure 7, Figure 8),
whereas detectable induction of al-ACT
required a 100-fold higher concentration
(10`1 M) (Figure 9). The other test com-
pounds caused detectable changes in the
expression levels ofTGFI3 and MAO-A at
doses similar to those required for pS2
induction, but for most chemicals, the con-
centrations required to induce al-ACTwere
10- to 100-foldhigher (Figure 9).
There are significant marker gene-depen-
dent differences in the rank order of poten-
cies of the test compounds (Table 3). For
example, the potencies ofE2, DES, and ZA
were essentially identical on TGEF3, whereas
the potencyofZAwas almost 100-fold lower
than the potencyofE2 and DES onpS2, al-
ACT, and MAO-A. Furthermore, NP and
GS affected the expression levels ofpS2 and
TGF33 with similar potencies, whereas the
potency of NP was almost 10-fold higher
than the potency of GS on MAO-A; the
potency of NP on al-ACTwas lower than
thatofGS (Table 3).
The partial estrogen agonist 4-OH-TAM
slightly increased expression levels of al-
ACT and pS2 and reduced the expression
level of MAO-A, suggesting that 4-OH-
TAM acts as a partial agonist on these genes.
In contrast, a high concentration of4-OH-
TAM slightly increased the expression of
TGF[3 (Figure 9), suggesting that it acts as
an antagonist or a selective estrogen receptor
modulator (SERM) on TGF133.
Discussion
In this paper we demonstrate that the
estrogenic activity ofa chemical can be eval-
uated by assaying induction or repression of
endogenous estrogen-regulated marker genes
in human estrogen-dependent breast cancer
cells. We also show that changes in gene
expression levels quantitatively show a
dose-response correlation. However, the
endogenous gene expression assay is more
time consuming and therefore less suited for
large-scale screening ofchemical compounds
than other more simple in vitroassays.
The comparison of expression levels
determined by PCR is a well-characterized
Table 3. Rank order of potencies ofthe estrogenic
compounds on four marker genes.
Marker gene Rank order of potency
pS2 E2=DES>ZA>NP=GS>MC>
ES = BisA > DODE> DBP
al-ACT E2=DES>ZA>GS>NP>ES>
BisA = MC> DDE> DBP
MAO-A E2>DES>ZA>NP>GS>DBP>
BisA > ES = MC > DDE
TGFf3 E2=DES=ZA>NP=GS>
BisA > MC > DDE> ES = DBP
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method used in a variety of protocols. PCR
amplification of cDNA fragments conserves
the relative levels as they were in the original
mRNA preparations, provided proper proce-
dures are used (38,39). Thus, the level ofan
amplified radioactivelylabeled PCRfragment
is direcdy proportional to the level ofthe cor-
responding mRNA in the original sample.
Thelow-stringency PCRmethod we describe
is, in principle, similar to multiplex PCR, in
which a few DNA fragments are amplified in
the same reaction, although we obtain multi-
plexing using a single primer pair and low-
stringency annealing. The result is that we
amplify on average approximately 125 PCR
fragments in each reaction. Because the com-
peting fragments are identical in all samples
prepared with a given primer pair, only the
level ofthe estrogen-sensitive mRNA/cDNA
fragment will change, and the intensityofthe
corresponding band accurately reflects the
level of the mRNA in the RNA samples.
However, in contrast to Northern blotting,
for example, the precise amount of an
mRNA is not reflected in the intensity ofthe
band. The DDRT-PCR technology only
allows comparison ofthe expression level ofa
given mRNA among different samples,
where the ratio between any two samples will
show the difference in the expression level of
the mRNAin the twosamples.
The expression levels were quantitated
by phosphor imaging scanning and normal-
ized according to either a constant band or
the background; this resulted in reproducible
results and thus accurate estimates ofestro-
genic activity. This is shown by the small
variation introduced in the cDNA synthesis
and PCR (24 and 16%, respectively), as
compared to the many fold induction or
repression resulting from exposure to the
estrogenic compounds.
The Marker Genes
In this study, estrogenicity was determined
by analyzing the expression levels of four
marker genes: pS2, MAO-A, TGFf3, and
al-ACT. Because the assay is based on
endogenous gene expression, an arbitrary
number ofmarker genes could, in principle,
be included in the assay; the marker genes
used in this study could be replaced by other
estrogen-responsive genes such as the proges-
terone receptor.
PS2. The expression level ofpS2 mRNA
is a widely used indicator of estrogenicity,
and the translation product ofpS2 mRNA is
also induced in MCF-7 cells in response to
estrogen (37). The 9 kDa encoded pS2 pro-
tein belongs to the trefoil family ofpeptides
(40), whose members are probably involved
in regulation of proliferation; it has been
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shown that trefoil proteins activate the
Ras/MEK/MAP-kinase signal transduction
pathwaybydirect interaction with epidermal
growth factor receptors (41). There are cur-
rently no reports in the literature of none-
strogenic compounds that induce pS2
expression in MCF-7 cells.
The human pS2 gene (accession no.
X05030; EMBL/EBI, Cambridge, UK) (42)
contains an imperfect estrogen response ele-
ment (ERE) that varies from the consensus
palindromic ERE (GGTCANNNTGACC)
by one base pair in its right arm (GGT-
CACGGTGGCC) (43). Functional imper-
fect EREs have been demonstrated in a
number ofestrogen responsive genes, includ-
ing human TGFax (44), human cathepsin D
(45), rat progesterone receptor (46), and
Xenopus laevis vitellogenin genes (47), and
are most likely responsible for the observed
estrogen-dependent regulation.
MAO-A. The MAO-A gene encodes one
ofthe two monoamine oxidase proteins (A).
The expression and activity ofMAO genes
(A and B) have been investigated both in
vivoand in vitro (48-50). In vivoassays have
been conducted because there seems to be a
correlation between mood changes and estra-
diol levels that may be mediated through the
activity of monoamine oxidases (51-53).
The activity and expression of MAO-A is
inversely correlated both in vivo and in vitro
to the estradiol concentration (49,50), which
is similar to the regulation we have observed
in MCF-7 cells. However, MAO genes may
be induced by E2 in some tissues; Sarabia
and Liehr (54) showed that expression ofthe
MAO-B gene actually is induced by E2 in
hamster kidneys.
The human MAO-A gene (accession no.
AL020990; EMBL/EBI) contains several
putative ERE sequences that could be respon-
sible for theobserved estrogen-dependent reg-
ulation ofthe MAO gene. One is located 200
base pairs upstream from the transcription
4-0
DBP ES 4-OH-TAM ICI1827W0
Figure 7. Dose-dependent induction of pS2 in MCF-7 cells by different estrogens. MCF-7 cells were
exposed for 24 hr to E2, DES, ZA, GS, NP, Bis-A, MC, DDE, DBP, ES, 4-OH-TAM, and ICI 182.780. Control
cells were exposed to ethanol (EtOH) or ICI 182.780 (10-7 M) for 24 hr. The band corresponding to pS2
(indicated by arrows) was detected by DDRT-PCR using the pS2 and HT11G primers. Quantitation of the
expression levels is shown in Figure 8.
Concentration (M)
Figure 8. Quantitative representation of DDRT-
PCR expression profiles. The fold induction is rel-
ative to EtOH, and the molar concentrations are
indicated. To eliminate lane-to-lane variations, we
normalized the quantitations according to the
background in each lane. The results represent at
leasttwo tothree independentexperiments.
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Figure 9. Phosphor imaging estimates ofthe dose-dependent effects of estrogens on the expression level
of (A) al-ACT, (B) MAO-A, and (C) TGFP3 using the following primers: pS2/HTllG (pS2), al-antichy-
motrypsin/HT11C (al-ACT),TGFJ3/HT11AG(TGFP3), and monoamine oxidaseNHT11GG (MAO-A)(Tables 1
and 2). MCF-7 cells were exposed to increasing concentrations of the test compounds and harvested
after 24 hr. Fold induction/repression is relative to ethanol (EtOH). Bands corresponding to each of the
three marker genes were detected by DDRT-PCR, and the expression profiles were quantitated by phos-
phor imaging. An example of a DDRT-PCR expression profile (corresponding to E2-exposed cells) appears
as an insert in each chart. The results represent at leasttwo tothree independent experiments.
initiation site and differs from the consensus
palindromic ERE by 2 base pairs in its right
arm (GGTCACCTTCCC). Moreover, the
two half-palindromic sequences are separated
by only 2 base pairs. Another putative imper-
fect ERE is located approximately 1,500 base
pairs upstream from the transcription initia-
tion site and contains a single mismatch in
the left arm (GGACAAATGTGACC), with
4 base pairs between the two half-palin-
dromic sequences.
TGF,B3. Repression ofTGF,3 expression
by estradiol in MCF-7 cells has previously
been described (55), and cell- and tissue-type-
specific expression has also been shown (56).
TGF33 expression is regulated by non-
estrogeniccompounds (57), and it isprobably
necessary to include additional marker genes
to be sure that only estrogens are detected.
Knabbe et al. (58) reported that TGFP3
inhibits the growth ofMCF-7 cells and that
secretion ofTGF,3 is induced by antiestro-
gens. In ourstudy, however,TGFP3 was only
slightlyincreased afterexposure to ahigh con-
centrationof4-OH-TAM (Figure9).
The human TGFI3 sequence (accession
no. X14885; EMBL/EBI) (59) contains a
putative imperfect ERE 340 base pairs
upstream from the transcription initiation
site, which varies from the con-sensus ERE
sequence at two positions, one in each half-
palindromic sequence (GGCCAGCAAC-
TGCCC). Also, the two half-palindromic
sequences are spaced by 5 base pairs, instead
of3.
al-ACT. Estrogen-mediated induction
has previously been described for the
antiprotease al-ACT in human breast can-
cercells (60,61).
The human al-ACTgene (accession no.
AL049839; EMBL/EBI) contains a putative
ERE sequence approximately 570 base pairs
upstream from the transcription initiation
site; however, as observed for TGE13, the
ERE differs from the consensus sequence at
two positions, one in each arm (AGT-
CACTGTGGCC).
Other genes could be included in the
assay, including genes regulated by either
ERa or ,B, together with genes regulated by
other pathways. The results presented in this
paper are most likely only derived from acti-
vation of ERa because we have not been
able to detect the ERi mRNA in MCF-7
cells by RT-PCR. However, we cannot rule
out that newly identified receptors such as
SXR and PXR [reviewed by Blumberg and
Evans (62)], which are activated by a variety
of different compounds, including estrogen
antagonists and agonists, could be involved
in the activation/repression of some of the
estrogen-sensitive genes we have identified.
The reversal ofestrogen-induced changes by
ICI 182.780 observed for the four marker
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genes, however, makes it unlikely that these
genes are regulated through the new recep-
tors (i.e., SXRand PXR).
Marker genes are often highly cell-type
specific. For example, MAO-A and TGFf3
were expressed in the estrogen-dependent
breast cancer cell line T47D, and both were
repressed byestrogens; pS2 was undetectable;
and the expression level ofal-ACT was very
low, much below that in MCF-7 cells,
although it probably is also induced by estro-
gen in T47D cells (results not shown). Thus,
the diverse action of estrogens on different
tissues and cell types is reflected in the genes
that are estrogen regulated in the different
cells; this suggests thatcell-specific differences
in gene expression might be exploited for the
detection ofnewSERMs.
Compounds have differentpotencies on
differentgenes. We demonstrated estrogenic
activity for all the putative estrogenic test
compounds, and the results correlate well
with previous reports (9,11,19). Furthermore,
because of its conversion to estrogens (63),
10-7 M testosterone had an estrogen-like
effect on the expression ofthe marker genes,
whereas 10-7 M progesterone hadno effect on
theexpression levels (results notshown).
The four marker genes all responded
strongly to the high-potency compounds (E2,
DES, and ZA), but there were some differ-
ences in their potency, defined as the mini-
mum concentration required to affect the
expression ofa markergene. The potencies of
E2 and DES were similar when assayed with
pS2, TG113, and a(-ACT, whereas MAO-A
seems to be more sensitive to E2 than to
DES. The potencyofZAwas equal to that of
E2 and DES if assayed with TGFI3, but it
was more than 10-fold lower than E2 and
DES for the otherthree markergenes.
The potencies of the environmental
estrogens were much lower than those ofE2,
DES, and ZA. As for the high-potency com-
pounds, there were some differences in the
relative potencies of the low-potency com-
pounds on the four genes (Table 3). For
example, the potency ofNP was equal to the
potencyofGS on two marker genes (pS2and
TGf143), but 10- to 100-fold higher and
lower, respectively, when assayedwith MAO-
Aandal-ACT
The relative potency of the compounds
generally correlated with the relative change
in expression level ofthe fourgenes, although
this was most evident forpS2. For example,
the expression level of pS2 was induced
almost 25-fold after exposure to 10-10 M E2,
approximately 16-fold after exposure to 102
M GS, and < 10-fold after exposure to i04
M DBP. For the other marker genes, this
trend was less consistent. Fold induc-
tion/repression is very sensitive to the initial
levels, and a slightly elevated level in the
noninduced cells leads to significant variation
in the fold change. Thus, the precise fold
change varies between experiments, whereas
the relative differences between compounds
are maintained.
High concentrations (108_10-6 M) of
TAM-OH seem to have small but detectable
E2-like effects on the expression ofMAO-A,
pS2, and al-ACT, whereas similar concen-
trations may have a small stimulatory effect
on TGF33. However, the required concen-
trations are so high that the effects may not
be ER mediated; this is similar to what has
been observed in SK-N-BE/SK-ER3 cells, in
which the observed effects of tamoxifen
apparently are independent of the presence
ofERa. Unfortunately, the possible expres-
sion ofER,I has not been investigated in the
SK-N-BE cells, although the lack of E2
response indicates that neither receptor sub-
type is present (48,49).
During the screening for estrogen-regu-
lated genes, we detected several related genes
that were consistently more sensitive to DES
and ZA than to E2. These genes, however,
show a time-dependent expression profile
that is different from the majority of the
identified E2-regulated genes; their expres-
sion was not affected before 8-16 hr expo-
sure to the hormones (35), whereas almost all
other E2-regulated genes, including the four
markergenes, were affectedwithin 2-8 hr.
Future development. There are many
aspects of the endogenous gene expression
assay that could be improved. For example,
we are assaying expression levels by radioac-
tive incorporation during PCR, but fluores-
cent labels could be used instead, with the
results analyzed on a DNAsequenator. In our
hands, however, fluorescent labels reduce the
sensitivityby 10- to 100-fold, although itmay
be possible to optimize both the PCRand the
detection thereby obtaining a sensitivity that
is similar to that ofradioactivity-based assays.
The Taq-Man technology (Perkin-Elmer)
maybe an atractive alternative. Anotherpossi-
bility is DNA chip technology (64,65). For
example, construction ofa chip with approxi-
mately 100 estrogen-regulated genes and a
similar number of unaffected genes would
allow almost complete automation of the
assay. However, at present, the sensitivity of
the chip technology limits its practical use;
this will probablychange, so DNAchip tech-
nology should be considered an alternative to
PCR-based methods.
Endogenous gene expression assays could,
in principle, be used to evaluate cellular
responses to any compound, provided genes
that respond to that dass ofcompounds have
been identified. Thus, compounds acting
through the androgen, thyroid, aromatic
hydrocarbon, and other receptors could be
identified bydetermining the expression levels
of genes that are activated through these
receptors. Assays to detect effects caused by
activation ofER[ and the androgen receptor
could be developed relatively easily from cell
lines derived from theprostate.
Furthermore, endogenous gene expression
assays are not limited to cell cultures because
changes in expression levels ofselected genes
could be determined in different tissues from
exposed animals. The number of animals
required to assay thousands ofcompounds for
their estrogenicity could be significantly
reduced ifgene expression-related end points
could be established. For example, when the
specific genes responsible for estrogen-induced
uterine or breast growth have been identified
and a relationship established between their
expression and a disease, these genes could be
assayed. An end point could then be fold
induction ofgenes X and Y in tissue A and
foldrepression ofgene Zin tissue B.
Finally, an ultimate goal would be to
develop an assay to directly analyze human
samples, for example, derived from blood.
This requires identification of genes
expressed in blood cells that are affected by
exposure to putative endocrine-disruptor
compounds. We are currently analyzing
blood samples for the expression of the E2-
regulated genes that we indentified in the
screening; preliminary results suggest that
many ofthe genes which are regulated by E2
in MCF-7 cells are also expressed in various
cells present in blood. However, we current-
ly do not have information concerning pos-
sible E2 regulation in the blood, although
reports in the literature suggested that there
are E2-regulated genes in blood and that, for
example, MAO-A may be a candidate for an
E2-regulated gene which could be assayed in
human blood samples. (48).
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